Microtubule-Associated Protein Tau, α-Tubulin and βIII-Tubulin Expression in Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The microtubule-associated protein Tau binds to both inner and outer surfaces of microtubules, leading to tubulin assembly and microtubule stabilization. The aim of this study was to evaluate the significance of Tau, α-tubulin, and βIII-tubulin expression in breast carcinoma and to assess their relationships with disease progression in the context of taxane treatment. Methods: Immunohistochemical expressions of Tau, α-tubulin, and βIII-tubulin were assessed in 183 breast cancer cases. Expression was correlated with clinicopathologic parameters, disease progression and overall survival. Results: Tau expression was correlated with lymph node metastasis and estrogen receptor (ER) positivity (p=.003 and p<.001, respectively). Loss of α-tubulin was significantly correlated with distant metastasis (p=.034). Loss of βIII-tubulin was correlated with lymph node metastasis and ER positivity (p=.004 and p<.001, respectively). In taxanetreated cases, Tau expression and loss of α-tubulin and βIII-tubulin expression were related to disease progression (p=.001, p=.028, and p=.030, respectively). Tau expression was associated with a worse survival rate in taxane-treated patients (p=.049). Conclusions: Tau expression and loss of α-tubulin and βIII-tubulin expression were correlated with aggressive behavior in taxane-treated breast cancer. Further evaluation of Tau, α-tubulin and βIII-tubulin may be useful in predicting clinical behavior and seeking therapeutic measures in taxane-based chemotherapy for breast cancer.
Abstract
Background: The microtubule-associated protein Tau binds to both inner and outer surfaces of microtubules, leading to tubulin assembly and microtubule stabilization. The aim of this study was to evaluate the significance of Tau, α-tubulin, and βIII-tubulin expression in breast carcinoma and to assess their relationships with disease progression in the context of taxane treatment. Methods: Immunohistochemical expressions of Tau, α-tubulin, and βIII-tubulin were assessed in 183 breast cancer cases. Expression was correlated with clinicopathologic parameters, disease progression and overall survival. Results: Tau expression was correlated with lymph node metastasis and estrogen receptor (ER) positivity (p=.003 and p<.001, respectively). Loss of α-tubulin was significantly correlated with distant metastasis (p=.034). Loss of βIII-tubulin was correlated with lymph node metastasis and ER positivity (p=.004 and p<.001, respectively). In taxanetreated cases, Tau expression and loss of α-tubulin and βIII-tubulin expression were related to disease progression (p=.001, p=.028, and p=.030, respectively). Tau expression was associated with a worse survival rate in taxane-treated patients (p=.049). Conclusions: Tau expression and loss of α-tubulin and βIII-tubulin expression were correlated with aggressive behavior in taxane-treated breast cancer. Further evaluation of Tau, α-tubulin and βIII-tubulin may be useful in predicting clinical behavior and seeking therapeutic measures in taxane-based chemotherapy for breast cancer.
참고문헌 (18)
- DeSantis C, "Breast cancer statistics, 2011", CA Cancer J Clin, 61, pp.409~418 (2011)
- Ikeda H, "The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells", Breast Cancer Res, 12, pp.R43~ (2010)
- Pusztai L, "Markers predicting clinical benefit in breast cancer from microtubule-targeting agents", Ann Oncol, 18(Suppl 12), pp.15~20 (2007)
- Wang Y, "High expression of class III beta-tubulin predicts good response to neoadjuvant taxane and doxorubicin", cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer, 2013, pp.13, 103~108
- Bernard-Marty C, "Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study", Clin Breast Cancer, 3, pp.341~345 (2002)
- Rouzier R, "Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer", Proc Natl Acad Sci U S A, 102, pp.8315~8320 (2005)
- Andre F, "Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer", Clin Cancer Res, 13, pp.2061~2067 (2007)
- McGrogan BT, "Taxanes, microtubules and chemoresistant breast cancer", Biochim Biophys Acta, 1785, pp.96~132 (2008)
- Tanaka S, "Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer", Cancer Chemother Pharmacol, 64, pp.341~346 (2009)
- Chen X, "Measuring beta-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer", Cancer Sci, 103, pp.262~268 (2012)
- Li ZH, "proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy", Med Oncol, 30, pp.591~ (2013)
- Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up", Histopathology, 19, pp.403~410 (1991)
- Smoter M, "The role of Tau protein in resistance to paclitaxel", Cancer Chemother Pharmacol, 68, pp.553~557 (2011)
- Shao YY, "Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin", Jpn J Clin Oncol, 40, pp.286~293 (2010)
- Pentheroudakis G, "microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial", Breast Cancer Res Treat, 116, pp.131~143 (2009)
- Niu Y, "Increased expression of centrosomal alpha, gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast", Cancer Sci, 100, pp.580~587 (2009)
- Banerjee A, "Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells", Biochem Biophys Res Commun, 293, pp.598~601 (2002)
- Yuan SF, "Expression of beta-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel", Asian Pac J Cancer Prev, 13, pp.361~365 (2012)